[{"orgOrder":0,"company":"Pharm-Olam","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharm-Olam","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharm-Olam \/ US Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"Pharm-Olam \/ US Department of Defense"},{"orgOrder":0,"company":"Pharm-Olam","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VLA2001","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharm-Olam","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharm-Olam \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharm-Olam \/ Undisclosed"},{"orgOrder":0,"company":"Pharm-Olam","sponsor":"NeRRe Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Orvepitant Maleate","moa":"TACR1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pharm-Olam","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharm-Olam \/ Pharm-Olam","highestDevelopmentStatusID":"8","companyTruncated":"Pharm-Olam \/ Pharm-Olam"},{"orgOrder":0,"company":"Pharm-Olam","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SER-262","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Pharm-Olam","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharm-Olam \/ Pharm-Olam","highestDevelopmentStatusID":"6","companyTruncated":"Pharm-Olam \/ Pharm-Olam"},{"orgOrder":0,"company":"Pharm-Olam","sponsor":"Helix BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"L-DOS47","moa":"Vascular endothelial growth factor receptor 2 (KDR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharm-Olam","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharm-Olam \/ Pharm-Olam","highestDevelopmentStatusID":"7","companyTruncated":"Pharm-Olam \/ Pharm-Olam"}]